

July 8, 2015



VolitionRx CSO Dr. Jake Micallef to Present Scientific Webinar

Presentation and Live Q&A on Wednesday, July 15, 2015 at 2pm US EDT

NAMUR, Belgium, July 8, 2015 /PRNewswire/ --[VolitionRx Limited](#) (NYSE MKT: VNRX) today announced that its Chief Scientific Officer, Dr. Jake Micallef, will present an informational webcast on July 15 about the company's blood-based diagnostic tests for a broad range of cancers and other conditions. Dr. Micallef will discuss challenges for current cancer diagnostics and the need for improved technology, and give an overview of the science behind VolitionRx's unique Nucleosomics[®] technology platform. He will also give an introduction to the clinical programs assessing VolitionRx's blood-based NuQ[®] cancer screening tests for the detection of the most prevalent cancers.

During the webcast Dr. Micallef will outline the importance of early cancer detection, differentiators of VolitionRx's diagnostics platform, and how VolitionRx is addressing an unmet need in global medicine by developing non-invasive, accurate, cost-effective and scalable cancer blood-based diagnostics. A live question and answer session will follow the presentation.

Details of the webcast are as follows:

Event: VolitionRx Webcast
Date: Wednesday, July 15, 2015
Time: 2:00 p.m. EDT

Participants can reserve their spot by registering at <http://volitionrx.dealflow.com/webcast2/>. Participants unable to join can register and will be sent the recording.

About VolitionRx

VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream - an indication that cancer is present.

VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.

Visit VolitionRx's website (www.volitionrx.com) or connect with us on [Twitter](#), [LinkedIn](#), [Facebook](#) or [YouTube](#).

Media Contacts

Anita Heward, VolitionRx

a.heward@volitionrx.com

Telephone: +44 (0) 7756 034243

Kirsten Thomas, The Ruth Group

kthomas@theruthgroup.com

Telephone: +1 (646) 536-7014

Investor Contacts

Scott Powell, VolitionRx

S.Powell@volitionrx.com

Telephone: +1 (646) 650-1351

Lee Roth, The Ruth Group

lroth@theruthgroup.com

Telephone: +1 (646) 536-7012

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of the Company's blood-based diagnostic test as well as the Company's ability to develop and successfully commercialize such test platform for early detection of cancer. The Company's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties include the Company's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in the Company's development pipeline or any other diagnostic products the Company might develop; the Company will face fierce competition and the Company's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as other documents that the Company files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, the Company does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/volitionrx-cso-dr-jake-micallef-to-present-scientific-webinar-300110190.html>

SOURCE VolitionRx Ltd